Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study

• Published in: BMJ (Online) 2020-10, Vol.371, p.m3503-m3503
• Main Authors: Mazariego, Carolyn G, Egger, Sam, King, Madeleine T, Juraskova, Ilona, Woo, Henry, Berry, Martin, Armstrong, Bruce K, Smith, David P
• Format: Article
• Language: English
• Subjects: Androgens; Brachytherapy; Cancer surgery; Cancer therapies; Diagnosis; Drug dosages; Erectile dysfunction; Intestine; Medical prognosis; Mens health; Patients; Population; Population studies; Population-based studies; Prostate cancer; Prostatectomy; Quality of life; Questionnaires; Radiation therapy; Surgery; Surveillance; Urinary incontinence; Urological surgery
• ISSN: 1756-1833; 0959-8138; 1756-1833
• DOI: 10.1136/bmj.m3503

AbstractObjectiveTo assess treatment related changes in quality of life up to 15 years after diagnosis of localised prostate cancer.DesignPopulation based, prospective cohort study with follow-up over 15 years.SettingNew South Wales, Australia.Participants1642 men with localised prostate cancer, aged less than 70, and 786 controls randomly recruited from the New South Wales electoral roll into the New South Wales Prostate Cancer Care and Outcomes Study (PCOS).Main outcome measuresGeneral health and disease specific quality of life were self-reported at seven time points over a 15 year period, using the 12-item Short Form Health Survey scale, University of California, Los Angeles prostate cancer index, and expanded prostate cancer index composite short form (EPIC-26). Adjusted mean differences were calculated with controls as the comparison group. Clinical significance of adjusted mean differences was assessed by the minimally important difference, defined as one third of the standard deviation (SD) from the baseline score.ResultsAt 15 years, all treatment groups reported high levels of erectile dysfunction, depending on treatment (62.3% (active surveillance/watchful waiting, n=33/53) to 83.0% (non-nerve sparing radical prostatectomy, n=117/141)) compared with controls (42.7% (n=44/103)). Men who had external beam radiation therapy or high dose rate brachytherapy or androgen deprivation therapy as primary treatment reported more bowel problems. Self-reported urinary incontinence was particularly prevalent and persistent for men who underwent surgery, and an increase in urinary bother was reported in the group receiving androgen deprivation therapy from 10 to 15 years (year 10: adjusted mean difference −5.3, 95% confidence interval −10.8 to 0.2; year 15: −15.9; −25.1 to −6.7).ConclusionsPatients receiving initial active treatment for localised prostate cancer had generally worse long term self-reported quality of life than men without a diagnosis of prostate cancer. Men treated with radical prostatectomy faired especially badly, particularly in relation to long term sexual outcomes. Clinicians and patients should consider these long term quality of life outcomes when making treatment decisions.